PROTEOME SCIENCES PLC

Director's Dealing • Apr 14, 2023

National Storage Mechanism | Additional information

RNS Number : 2803W

Proteome Sciences PLC

14 April 2023

14 April 2023

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Director/PDMR Shareholding

The Company has received notification from Vulpes Investment Management Pte Ltd ("Vulpes") that on 12 and 13 April 2023 it purchased, respectively, 100,000 and 100,000 ordinary shares of 1p in the capital of the Company ("Ordinary Shares") at a price of 4p per Ordinary Share (the "Purchase"). Following the Purchase, Vulpes has a total direct and indirect interest in 67,789,772 Ordinary Shares, equivalent to 22.97% of Proteome Sciences' total issued share capital.

By virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 67,789,772 Ordinary Shares of the Company representing 22.97% of the issued share capital of the Company.

The below notification is made in accordance with the requirements of the Market Abuse (amendment) (EU Exit) Regulations 2019/310.

1.     

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Martin Diggle

Reason for the notification

a)

Position/status:

Non-Executive Director

b)

Initial notification/Amendment:

Initial Notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Proteome Sciences Plc

b)

LEI:

213800Q62ICXANKU2986

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary Shares of 1p nominal value

GB0003104196

b)

Nature of the transaction:

Purchase of Ordinary Shares

c)

Price(s) and volume(s):

Price(s)	Volume(s)
4.00p	100,000
3.90p	100,000

d)

Aggregated information:

·    Aggregated volume:

·    Price:

Single transaction as in 4 c) above

Average Price	Volume(s)
3.95p	200,000

e)

Date of the transaction:

12 and 13 April 2023

f)

Place of the transaction:

London Stock Exchange, AIM (XLON)

For further information please contact:

Proteome Sciences plc
Dr. Mariola Soehngen, Chief Executive Officer Dr. Ian Pike, Chief Scientific Officer	Tel: +44 (0)20 7043 2116
Richard Dennis, Chief Commercial Officer Abdelghani Omari, Chief Financial Officer
Allenby Capital Limited (Nominated Adviser & Broker)
John Depasquale / Jeremy Porter	Tel: +44 (0) 20 3328 5656

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHSFUSULEDSEDL